Why the study?
Does empagliflozin reduce heart failure and renal events in patients with type 2 diabetes mellitus, established cardiovascular disease, and atrial fibrillation?
Does empagliflozin reduce heart failure and renal events in patients with type 2 diabetes mellitus, established cardiovascular disease, and atrial fibrillation?
Patients with type 2 diabetes, cardiovascular disease, and atrial fibrillation derive a high absolute benefit from empagliflozin for preventing heart failure and renal events.
Greater absolute benefit in AF patients supports prioritization; confirms efficacy irrespective of AF in T2DM with CVD.
In patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF-related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.
No takes yet. Share an insight, caveat, or question.
Böhm et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: